Vitamin K antagonist

Cadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients with LVADs, RVADs, Biventricular Assist Devices, and Total Artificial Hearts

Retrieved on: 
tisdag, april 9, 2024
ODD, Warfarin, Thrombosis, VADS, Risk, Vitamin K antagonist, New Drug Application, Patient, Apixaban, Stroke, Anticoagulant, Splenic infarction, Death, Therapy, Bleeding, LVAD, FDA, VKA, Pharmaceutical industry

PONTE VEDRA, Fla., April 9, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions, announced today that the United States Food and Drug Administration (FDA) has granted tecarfarin Orphan Drug Designation (ODD) for the prevention of thromboembolism and thrombosis in patients with an implanted mechanical circulatory support device (left ventricular assist device (LVAD), right ventricular assist device (RVAD), collectively known as ventricular assist devices (VADs), biventricular assist device, and total artificial heart).

Key Points: 
  • "This second orphan drug designation highlights the expanded need for tecarfarin where existing anticoagulation therapies are inadequate," said Quang Pham, Founder, Chairman and Chief Executive Officer of Cadrenal Therapeutics.
  • "We are dedicated to advancing tecarfarin through clinical development options as swiftly as possible."
  • Since its adoption in 1983, the Orphan Drug Act has helped countless individuals living with these conditions gain access to life-enhancing and life-saving therapies.
  • The designation is made to promote safe and efficacious products for the treatment of rare conditions.

Cadrenal Therapeutics Appoints Jeff Cole as Chief Operating Officer in Advance of Tecarfarin Phase 3 Pivotal Trial

Retrieved on: 
torsdag, februari 8, 2024
Principal, Kidney disease, Corporate development, Ventricular fibrillation, Therapy, OTC, University, Vitamin K antagonist, Financial management, Antiphospholipid syndrome, ESKD, Patient, Atrial fibrillation, APS, PwC, Intellectual property, VKA, Management

In this role, Mr. Cole will be responsible for the Company's manufacturing and supply chain operations, intellectual property, commercialization strategies, and supporting partnering activities for tecarfarin.

Key Points: 
  • In this role, Mr. Cole will be responsible for the Company's manufacturing and supply chain operations, intellectual property, commercialization strategies, and supporting partnering activities for tecarfarin.
  • Mr. Cole brings over 25 years of experience in global pharmaceutical manufacturing and commercial operations, finance, and corporate development to the Company.
  • His experience will serve Cadrenal well as we advance our tecarfarin clinical program and evaluate partnering opportunities," commented Quang Pham, Founder, Chairman and Chief Executive Officer of Cadrenal Therapeutics.
  • "I look forward to leveraging my experience to advance tecarfarin to the market and help those underserved patient groups."

The global anticoagulants market was valued at $24,265 million in 2017, and is expected to reach $43,427 million by 2025, growing at a CAGR of 7.5% from 2018 to 2025

Retrieved on: 
torsdag, december 13, 2018
Medicine, Blood tests, Blood, Heparins, Anticoagulants, Hematology, Medical signs, RTT, Low molecular weight heparin, Vitamin K antagonist, Coagulation, Vitamin K

Anticoagulants, commonly known as blood thinners, are chemical substances that prevent or reduce coagulation of blood and prolong the clotting time.

Key Points: 
  • Anticoagulants, commonly known as blood thinners, are chemical substances that prevent or reduce coagulation of blood and prolong the clotting time.
  • The market has different types of anticoagulant drugs, and each drug works by inhibiting various pathways of blood coagulation.
  • On the basis of drug class, the anticoagulants market is classified as NOACs, heparin & LMWH, vitamin K antagonist, and others.
  • The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.